Mineralys Therapeutics, Inc. (MLYS)
Nasdaq: MLYS · Pharmaceutical Preparations · Radnor, PA · filing with the SEC since 2022
Who owns Mineralys Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Catalys Pacific Fund, LP holds 10.1% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Feb 13, 2026 says.
Directors and officers
18
report now, of 21 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Catalys Pacific Fund, LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.0001 per share · 13.5% in Aug 14, 2025
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Sep 8, 2025 · Common Stock, par value $0.0001 per share · 9.9% in Mar 17, 2025
Srinivas Akkaraju
SCHEDULE 13D/A · filed Sep 8, 2025 · Common Stock · 9.1% in Mar 17, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 6.3% in Feb 5, 2026
Andera Partners
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Adams Street Partners, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
What MLYS reports owning in othersstakes of 5% or more, and other ties
Mineralys Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
79sales
2purchases
56sales on a scheduled plan
7people selling
$44.7Msold, in dollars
$8.8Mbought, in dollars
Open-market trades on Form 4 from Oct 20, 2025 to Oct 20, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 20, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 25 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10% owner | 1 | $43.4M | 0 | 0 | $0 |
| Congleton Jon | Chief Executive Officer | 16 | $16.2M | 10 | 0 | $0 |
| Rodman David Malcom | Chief Medical Officer | 38 | $14.0M | 38 | 0 | $0 |
| Levy Adam Scott | CFO and Secretary | 10 | $5.7M | 1 | 0 | $0 |
| Warren Eric | Chief Commercial Officer | 4 | $3.3M | 4 | 0 | $0 |
| Slingsby Brian Taylor | director | 1 | $3.0M | 0 | 0 | $0 |
| Gold Alexander M | director | 5 | $1.6M | 0 | 0 | $0 |
| Karydas Daphne | director | 5 | $900,000 | 3 | 0 | $0 |
| Shah Rajeev M. | director | 0 | $0 | 0 | 2 | $8.8M |